20
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before September 30, 2024

      About Blood Purification: 2.2 Impact Factor I 5.8 CiteScore I 0.782 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Sulindac Reduces the Urinary Excretion of Prostaglandins and Impairs Renal Function in Cirrhosis with Ascites

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In 5 patients with cirrhosis and ascites the glomerular filtration rate (GFR), free water clearance (CH<sub>2</sub>O) and urinary excretion of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and 6-keto-prostaglandin F<sub>1α</sub> (6-keto-PGF<sub>1α</sub>) were measured before and after a 3-day treatment with sulindac (400 mg/day). The administration of sulindac induced a marked fall of urinary excretion of PGE<sub>2</sub> (from 24.2 ± 5.5 to 3.8 ± 1.1 ng/h; p < 0.05), 6-keto-PGF<sub>1α</sub> (from 19.9 ± 2.9 to 5.6 ± 1.1 ng/h; p < 0.02) GFR (from 111 ± 15 to 67 ± 10 ml/min; p < 0.01) and CH<sub>2</sub>O (from 7 ± 1.5 to 3.7 ± 1.3 ml/min; p < 0.02) in all patients studied. The plasma concentration of the active metabolite sulindac sulfide in cirrhotics was 400% of that found in 6 healthy volunteers (9.6 ± 1.7 vs. 2.4 ± 0.6 ng/ml). Our results indicate that sulindac, at a dose of 400 mg/day, inhibits the renal synthesis of prostaglandins and impairs renal function in cirrhotics with ascites. These effects are probably related to the marked alteration of sulindac kinetics that occurs in these patients.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1986
          1986
          04 December 2008
          : 42
          : 4
          : 298-303
          Affiliations
          Liver Unit, Hormonal Laboratory and Toxicology Laboratory, Hospital Clínico y Provincial, University of Barcelona, Spain
          Article
          183692 Nephron 1986;42:298–303
          10.1159/000183692
          3515219
          f4c8b935-c3a6-40b2-9933-c1cafe1cef0a
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 29 July 1985
          Page count
          Pages: 6
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          Renal failure,6-Keto-prostaglandin-F1α ,Prostaglandin E2 ,Cirrhosis,Sulindac

          Comments

          Comment on this article